Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epidoxorubicin + carboplatin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Epidoxorubicin (EDX) + carboplatin (CBDCA) is a chemotherapy combination used primarily in the treatment of advanced ovarian cancer. Epidoxorubicin is an anthracycline antibiotic with antineoplastic properties, while carboplatin is a platinum-containing compound that works by stopping or slowing the growth of cancer cells. This combination exhibits nonoverlapping toxicities and has shown significant activity in advanced ovarian cancer patients. When added to platinum-based chemotherapy, epidoxorubicin has been shown to improve long-term survival in some studies.
- Other names
- 4-epidoxorubicin + carboplatin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epidoxorubicin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epidoxorubicin + carboplatin.